株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

淋病:パイプライン製品の分析

Gonorrhea - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 302503
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.35円で換算しております。
Back to Top
淋病:パイプライン製品の分析 Gonorrhea - Pipeline Review, H1 2017
出版日: 2017年03月15日 ページ情報: 英文 46 Pages
概要

淋病は、性感染症の一種で、男性にも女性にも感染の危険があり、特に尿道、直腸、食道、さらに女性には子宮にも多くの感染が認められます。

当レポートでは、淋病治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

淋病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

淋病:企業で開発中の治療薬

淋病:大学/機関で研究中の治療薬

淋病:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

淋病:企業で開発中の製品

淋病:大学/機関で研究中の製品

淋病の治療薬開発に従事している企業

  • Melinta Therapeutics, Inc
  • Cubist Pharmaceuticals, Inc.
  • Genocea Biosciences, Inc.

淋病:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • delafloxacin
  • solithromycin
  • 淋病ワクチン
  • 細菌およびウイルス感染症の治療薬
  • IL 12 NanoCap

淋病:最近のパイプライン動向

淋病:休止中のプロジェクト

淋病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9039IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H1 2017, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is an infection caused by a sexually transmitted bacterium that can infect both males and females. Gonorrhea most often affects the urethra, rectum or throat. In females, gonorrhea can also infect the cervix. Symptoms include painful urination, pus-like discharge from the tip of the penis, increased vaginal discharge, painful urination, abdominal pain and pelvic pain. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gonorrhea - Overview
  • Gonorrhea - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Gonorrhea - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gonorrhea - Companies Involved in Therapeutics Development
    • Debiopharm International SA
    • Entasis Therapeutics Inc
    • Merck & Co Inc
    • Recce Ltd
  • Gonorrhea - Drug Profiles
    • Debio-1453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edodekin alfa SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zoliflodacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gonorrhea - Dormant Projects
  • Gonorrhea - Discontinued Products
  • Gonorrhea - Product Development Milestones
    • Featured News & Press Releases
      • Oct 28, 2016: Entasis Therapeutics to Present Data on ETX0914 at IDWeek 2016
      • Sep 21, 2016: Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea
      • Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents
      • Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
      • Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
      • Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID
      • Oct 04, 2012: Cempra Announces Positive Top-Line Results From Solithromycin Phase II Clinical Trial In Patients With Uncomplicated Urogenital Gonorrhea
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gonorrhea, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Gonorrhea - Pipeline by Debiopharm International SA, H1 2017
  • Gonorrhea - Pipeline by Entasis Therapeutics Inc, H1 2017
  • Gonorrhea - Pipeline by Merck & Co Inc, H1 2017
  • Gonorrhea - Pipeline by Recce Ltd, H1 2017
  • Gonorrhea - Dormant Projects, H1 2017
  • Gonorrhea - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Gonorrhea, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top